SATIVEX: Esplendor en la "yerba" para Bayer

"Aunque mis ojos ya no puedan ver ese puro destello, que me deslumbraba.
Aunque ya nada pueda devolver la hora del esplendor en la hierba de la gloria en las flores, no hay que afligirse.
Porque la belleza siempre subsiste en el recuerdo....."

William Wordsworth

Era el "leitmotiv" en la "peli" de Kazan que "removió" nuestra adolescencia...
Natalie Wood...! (Natalia ponian los afiches en España por eso del "doblaje total"). Warren Beatty...!
Ufff...

Ahora es Bayer quien se lleva la "yerba" (no me sale escribirlo con dos l´s") al agua con SATIVEX.

Bayer Healthcare has launched the world’s first cannabis-derived prescription drug in the UK.

Sativex treats the spasticity symptoms of multiple sclerosis, such as spasms and cramps, and is manufactured with government permission at a secret UK location.

It is the first cannabinoid medicine to be derived from whole plant extracts of the cannabis sativa plant and contain both delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

Professor John Zajicek, a neurology consultant at Derriford Hospital in Plymouth, said Sativex’s launch was a milestone for cannabinoid medicines.

“Current standard therapy for MS-associated spasticity can produce side effects which patients may find difficult to cope with and not all of them are specifically licensed for spasticity.

“Sativex on the other hand has mainly mild to moderate side effects, which can be easily controlled by adjusting the dose. It has really benefited those people who have found it effective and is a useful addition to available treatments.”

Mas